Biomarkers Predict Lung Decline in Systemic Sclerosis PDF Print E-mail
Thursday, 20 September 2012 21:39
Predicting risk of pulmonary fibrosis and pulmonary hypertension is an urgent priority in systemic sclerosis. Lung function often declines rapidly in the first years after diagnosis, and interstitial lung disease (ILD), although highly variable in severity and disease coruse, is a major cause of mortality in systemic sclerosis.

Two ILD specialists at London's Brompton Hospital identify two biomarkers in peripheral blood as possibly simpler and better alternatives to the current best standard for prognosis, a staging system based on a combination of CT imaging and forced expiratory volume measurements.

Decreased FEV and decreased diffusing capacity of the lung for carbon monoxide are sensitive for interstitial lung disease, note the authors of the review in the International Journal of Rheumatology, but may indicate pulmonary vascular disease rather than ILD. The most promising tests specific for ILD in systemic sclerosis are KL-6, a glycoprotein in alveolar and bronchiolar epithelial cells whose serum levels rise after cellular injury, and CCL-18, an immune-system regulator in lung cells that is increased in a number of fibrotic lung diseases.

Serum levels of KL-6 are significantly higher in systemic sclerosis patients who have ILD than in those who don't, according to the review. The molecule has been used routinely to predict ILD in systemic sclerosis patients in Japan, but requires validation in prospective studies. In the first large study to test a prognostic biomarker for pulmonary decline in systemic sclerosis while adjusting for severity of lung disease, increased levels of CCL-18 were independently predictive of decreasing lung function and death.

Like many proposed biomarkers, these require validation by separate studies. At least two multicenter trials are currently under way to identify markers of prognosis in idiopathic pulmonary fibrosis. No such study has yet been launched for ILD in systemic sclerosis.

Source: UBM Medica (2012), "Biomarkers Found to Predict Lung Decline in Systemic Sclerosis"; Original article can be viewed at the MusculoskeletalNetwork

 
More articles :

» Autoimmune Disease Symptoms To Look Out For

We have understood for  a long time that the detection and subsequent diagnoses of autoimmune diseases are difficult. However, there are key rheumatic and physical indicators such as joint pain and fatigue, fevers, increasing skin conditions,...

» Rare Disease Research Teams Receive Over $17m In Funding

(CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...

» The Heart In Scleroderma

Just as can affect multiple organ systems, the cardiac manifestations of the disease are diverse. Although only relatively recently recognized, the heart is a major organ involved in Scleroderma and the presence of cardiac involvement generally...

» Preliminary Results Show Beneficial Effects of Imatinib in Scleroderma

Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing beneficial effects on skin and lung manifestations in patients with diffuse cutaneous scleroderma....

» B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence

Dimitrios Daoussis, Stamatis-Nick C. Liossis, Georgios Yiannopoulos, and Andrew P. AndonopoulosDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504 Patras,...